Supraphysiological levels of the incretin hormone glucagonlike peptide 1 (GLP-1) have demonstrated a marked glucoselowering effect in patients with Type 2 diabetes. Six GLP-1 receptor agonists are currently available for the treatment of Type 2 diabetes and have all proven to render significant reductions in both glycated haemoglobin level and body weight. However, of the clinical available compounds only liraglutide, dulaglutide and semaglutide have demonstrated reductions in the risk of cardiovascular disease. This review aims at providing an overview of the efficacy and safety of the GLP-1 receptor agonist class.